This study not only identified a novel molecular target (PLAC8) during LC progression but also identified the aberrant KLF4/PLAC8 signaling pathway as a promising new molecular target for the design of novel therapeutic modalities to suppress LC progression. This evidence concerns the gene KLF4 and laryngotracheoesophageal cleft.